🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT02795052
Recruiting Not applicable

Neurologic Stem Cell Treatment Study

NCT02795052 · tracked via the Priya Life Science USA tracker
Sponsor
MD Stem Cells
Phase
Not applicable
Started
2016-06
Last updated
2026-06-26

Condition(s) studied

Neurologic DisordersNervous System DiseasesNeurodegenerative DiseasesNeurological DisordersStrokeTraumatic Brain InjuryCadasilChronic Traumatic EncephalopathyCerebral InfarctionCerebral IschemiaCerebral StrokeCerebral HemorrhageParkinsonMulti-System DegenerationMSA - Multiple System AtrophyProgressive Supranuclear PalsyALSAmyotrophic Lateral SclerosisNeuropathyDiabetic NeuropathiesAlzheimer DiseaseDementiaFrontotemporal DementiaLewy Body DiseaseCognitive ImpairmentLewy Body Variant of Alzheimer Disease

Investigational drug(s) / intervention(s)

Intravenous and Intranasal BMSC

Intravenous and Intranasal BMSC: Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)

Study summary

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care. 2. Be at least 6 months post-onset of the disease. 3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment. 4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure. 5. Be over the age of 18 and capable of providing informed consent. 6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health. Exclusion Criteria: 1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam. 2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol. 3. Patients must be capable of providing informed consent. 4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. . 5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible. 6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
MD Stem Cells Westport Connecticut Recruiting
MD Stem Cells Coral Springs Florida Recruiting
The Saudi-German Hospital Dubai United Arab Emirates Recruiting

More MD Stem Cells trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02795052 on ClinicalTrials.gov ↗ ← All trials in the USA